1,3 Hypertensive emergencies are associated with acutely progressive

secondary organ damage (e.g., stroke or myocardial infarction [MI]). Hypertensive

urgency is not an immediately life-threatening situation; a reduction in BP to a safe

level can occur more slowly in the next 24 to 48 hours.

1,6

Acute, potentially life-threatening elevations of BP can occur in previously

normotensive individuals with acute glomerulonephritis, head injury, or severe

burns; during pregnancy (eclampsia); and with the use of recreational drugs such as

cocaine. Other causes include abrupt medication withdrawal or medication

nonadherence, drug–drug interactions (including herbal medications), erythropoietin

administration, or drug–food interactions (i.e., patients receiving monoamine oxidase

inhibitors who ingest foods rich in tyramine).

7–9

In addition, poor systolic BP control

has been identified as an independent risk factor for the development of hypertensive

crisis.

10 Despite improvements in the recognition and treatment of hypertension, there

has been an increase in the number of hospitalizations for hypertensive emergencies

in the United States from 2000 to 2007 (101–111 cases per 100,000

hospitalizations). Fortunately, in-hospital mortality associated with these admissions

decreased from 2.8% to 2.6% in this time period.

11

p. 333

p. 334

Table 16-1

Hypertensive Emergency versus Urgency

Emergency Urgency

Blood pressure

criteria

Diastolic >120 mm Hg

a Diastolic >120 mm Hg

a

Life-threatening Potentially Not acutely

End-organ damage Acute or progressing Chronic; not progressing

Clinical

manifestations

CNS (dizziness, N/V, encephalopathy, confusion,

weakness, intracranial or subarachnoid

hemorrhage, stroke)

Eyes (ocular hemorrhage or funduscopic

changes, blurred vision, loss of sight)

Cardiac (left ventricular failure, pulmonary

edema, MI, angina, aortic dissection)

Renal failure or insufficiency

Optic disc edema

Treatment strategy Immediate reduction in blood pressure; administer

parenteral therapy (Table 16-2)

Reduction in blood pressure over

several hours to days; administer oral

therapy (Table 16-3)

aDegree of blood pressure elevation less diagnostic than rate of pressure rise and presence of concurrent diseases

or end-organ damage. See Chapter 9, Essential Hypertension, for staging of hypertension.

CNS, central nervous system; MI, myocardial infarction; N/V, nausea and vomiting.

CLINICAL PRESENTATION OF HYPERTENSIVE

URGENCY

There are limited data describing the presentation and characteristics of those

patients with a hypertensive urgency. Symptoms may include headache, dizziness,

visual changes, chest discomfort, nausea, epistaxis, fatigue, and psychomotor

agitation.

12

It should be noted that not all patients presenting with a hypertensive

urgency will have symptoms.

CLINICAL PRESENTATION OF HYPERTENSIVE

EMERGENCY

Similar to hypertensive urgencies, hypertensive emergencies typically occur in those

with a history of hypertension. This suggests that hypertensive emergencies are

almost entirely preventable.

13,14 Hypertensive emergencies tend to occur in patients

with catecholamine-producing adrenal tumors (pheochromocytoma) or renal vascular

disease. Additionally, hypertensive emergencies occur more often in African

Americans than in Caucasians, among patients who have no primary care physician,

and those who do not adhere to treatment regimens.

13,15

Symptoms associated with hypertensive emergency are highly variable and reflect

the degree of damage to specific organ systems. Rapid, severe BP elevation is not

always the hallmark of a hypertensive emergency. The primary sites of damage are

the central nervous system, heart, kidneys, and eyes. Although hypertensive

emergencies are much less common than hypertensive urgencies, it is often difficult

to know whether end-organ dysfunction is new or has progressed without a thorough

patient history.

Central Nervous System

Central nervous system abnormalities are the most commonly reported complications

in hypertensive emergencies. Symptoms may include a severe headache with or

without dizziness, nausea, vomiting, and anorexia. Mental confusion with

apprehension indicates more severe damage, as does nystagmus, localized weakness,

or a positive Babinski sign (i.e., upward extension of the great toe and spreading of

the smaller toes when moderate pressure is applied along a curve from the sole to the

ball of the foot). Central nervous system damage may rapidly progress, resulting in

coma or death. If a cerebrovascular accident has occurred, slurred speech or motor

paralysis may be present.

13

Other Complications

Cardiac consequences are the second most common complication of hypertensive

emergency reported. Presentations may include heart failure (HF), acute pulmonary

edema, and/or an acute coronary syndrome. Ocular symptoms of hypertensive

emergency usually are related to changes in visual acuity. Complaints of blurred

vision or loss of eyesight are often associated with funduscopic findings of

hemorrhages, exudates (yellow deposits within the retina as a result of leaks from

capillaries and microaneurysms), and occasionally papilledema (edema of the optic

nerve). Acute kidney injury can also develop. Markers of renal dysfunction include

hematuria, proteinuria, and elevated serum blood urea nitrogen and serum creatinine

levels.

OVERVIEW OF TREATMENT

Oral versus Parenteral Therapy

Hypertensive urgency is not an indication for parenteral treatment; oral

antihypertensive regimens are more appropriate. Practitioners should exercise

caution in the treatment of patients with elevated BP in the absence of target organ

damage. Aggressive dosing to rapidly lower BP is not without risk and can lead to

hypotension and subsequent morbidity. Some have suggested that the term

hypertensive urgency leads to overly aggressive treatment and should be discarded in

favor of a less ominous term such as uncontrolled BP.

6

In contrast, hypertensive

emergencies require immediate hospitalization, generally in an intensive care unit,

and the administration of parenteral antihypertensive medications to reduce arterial

pressure.

16 Effective therapy greatly improves the prognosis, reverses symptoms, and

arrests the progression of end-organ damage.

17–19 Whether treatment can completely

reverse end-organ damage is related to two factors: how soon treatment is initiated

and the extent of damage at the initiation of therapy.

p. 334

p. 335

There are two fundamental concepts in the management of hypertensive

emergencies. First, immediate and intensive therapy is required and takes precedence

over time-consuming diagnostic procedures. Second, the choice of drugs will depend

on how their time course of action and hemodynamic and metabolic effects meet the

needs of the emergent situation. If encephalopathy, acute left ventricular failure,

dissecting aortic aneurysm, eclampsia, or other end-organ damage is present, the BP

should be lowered promptly with rapid-acting, parenteral antihypertensive

medications such as clevidipine, esmolol, enalaprilat, fenoldopam, hydralazine,

labetalol, nicardipine, nitroglycerin, or nitroprusside (Table 16-2).

1,3,4,20–24

If a

slower BP reduction over the course of several hours or days is acceptable, as in the

case of a hypertensive urgency, rapid-acting oral therapy using captopril, clonidine,

labetalol, or minoxidil may be used (Table 16-3).

3,4,24–26 Figure 16-1 provides an

overview of the management of a hypertensive crisis. A summary of treatment

recommendations for acutely lowering BP for selected indications is listed in Table

16-4.

p. 335

p. 336

Table 16-2

Parenteral Medications Commonly Used in the Treatment of Hypertensive

Emergencies

Medication (Brand

Name)/Class Dose/Route Onset of Action Duration of Action

Clevidipine

(Cleviprex)/calciumchannel blocker

Initial: 1–2 mg/hour; titrate dose to desired

BP or to a max of 16 mg/hour

2–4 minutes 10–15 minutes after

D/C infusion

Enalaprilat

a

(Vasotec IV)/ACE

inhibitor

0.625–1.25 mg IV every 6 hours 15 minutes (max, 1–

4 hours)

6–12 hours

Esmolol

b

(Brevibloc)/β-adrenergic

blocker

250–500 mcg/kg for 1 minute, then 50–300

mcg/kg/minute

1–2 minutes 10–20 minutes

Fenoldopam

(Corlopam)/dopamine1 agonist

0.1–0.3 mcg/kg/minute <5 minutes 30 minutes

Hydralazine

c

(generic) (20

mg/mL)/arterial

vasodilator

10–20 mg IV 5–20 minutes 2–6 hours

Labetalol

d

(Normodyne)/α- and

β-adrenergic blocker

2 mg/minute IV or 20–80 mg every 10

minutes up to 300 mg total dose

2–5 minutes 3–6 hours

Nicardipine

e

(Cardene

IV)/calcium-channel

blocker

Initiate at 5 mg/hour IV increased by 2.5

mg/hour every 5 minutes to desired BP or a

max of 15 mg/hour every 15 minutes, may

decrease to 3 mg/hour after response

achieved

2–10 minutes (max,

8–12 hours)

40–60 minutes after

D/C infusion

Nitroglycerin

f

(Tridil,

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more